ONMD · XBRL financial data

OneMedNet financial statements, every fiscal year

The same tables from 7 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (ONMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue	—	—	1,021	643	1,359
Revenue from contracts with customers	—	1,153	1,021	643	1,359
Cost of revenue	—	1,513	1,150	924	1,862
Gross profit	—	(360)	(129)	(281)	(503)
Research and development	—	1,591	2,065	1,467	1,515
General and administrative	—	4,806	3,544	7,027	6,377
Total operating expenses	—	7,355	6,724	9,324	9,164
Operating income (loss)	—	(5,309)	(6,853)	(9,605)	(9,667)
Interest expense	—	403	11	147	67
Other income (expense)	—	—	(34)	(25)	(16)
Income tax expense (benefit)	—	215	18	2	1
Net income (loss)	—	337	(33,780)	(10,129)	(2,801)
Earnings per share, basic USD per share	—	(7.66)	(4.77)	(0.36)	(0.06)
Earnings per share, diluted USD per share	—	0.03	(4.77)	(0.36)	(0.06)
Weighted average shares, basic thousands of shares	—	3,974	7,084	28,077	44,548
Weighted average shares, diluted thousands of shares	—	3,974	7,084	28,077	44,548

† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ONMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	453	31	47	172	585
Accounts receivable	—	19	152	213	495
Prepaid and other current assets	—	101	166	385	509
Total current assets	536	31	365	3,619	2,095
Property and equipment, net	—	83	99	108	56
Total assets	117,857	29,060	464	3,727	2,151
Accrued liabilities	—	1,680	—	—	—
Total current liabilities	290	1,976	13,373	19,228	4,825
Total liabilities	9,167	9,117	13,906	19,677	5,116
Accumulated deficit	(8,610)	(11,633)	(91,440)	(101,569)	(104,370)
Total stockholders' equity	(8,609)	(8,806)	(13,442)	(15,950)	(2,965)
Total liabilities and equity	117,857	29,060	464	3,727	2,151
Common shares outstanding (cover page) thousands of shares	—	4,033	23,850	30,761	52,197

† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

Fiscal years (ONMD's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023†Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	337	(33,780)	(10,129)	(2,801)
Stock-based compensation	—	2,826	1,475	628	2,032
Depreciation and amortization	—	25	28	57	65
Net cash from operating activities	—	(940)	(4,791)	(6,983)	(7,503)
Purchases of property and equipment	—	58	44	51	13
Net cash from investing activities	—	(2,246)	(44)	(1,982)	2,307
Repayments of long-term debt	—	—	—	200	—
Net cash from financing activities	—	2,764	4,611	9,090	5,609
Net change in cash	—	(422)	(224)	125	413

† Share count changed about 6x in the period ending 2023-12-31, likely a stock split with no split ratio in the XBRL data; figures before that column are not adjusted.

SIC 8731 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 8731 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
OneMedNet	358	292	(1,875)*	59.3M	0.2 quarters	Q2 FY26 10-QJun 30, 2026
IB Acquisition	30	not reported	(474)*	5.0M	0.1 quarters	Q3 FY26 10-QJun 30, 2026
bioAffinity Technologies	2,430	1,511	(3,201)*	8.1M	0.8 quarters	Q2 FY26 10-QJun 30, 2026
20/20 Biolabs	4,546	731	(605)*	12.8M	7.5 quarters	Q2 FY26 10-QJun 30, 2026
Hypha Labs	5.1	not reported	(52)*	163.9M	0.1 quarters	Q3 FY26 10-QJun 30, 2026
Cannabis Bioscience International Holdings	0.1	11	(15)*	11.6B	0.0 quarters	Q3 FY26 10-QFeb 28, 2026

Not investment advice. Not affiliated with the U.S. SEC.